A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes
Details
Publication Year 2023-02,Volume 98,Issue #2,Page 272-281
Journal Title
American Journal of Hematology
Publication Type
Research article
Abstract
Patients with relapsed/refractory (R/R) higher-risk myelodysplastic syndromes (MDS) have a dismal median overall survival (OS) after failing hypomethylating agent (HMA) treatment. There is no standard of care for patients after HMA therapy failure; hence, there is a critical need for effective therapeutic strategies. Herein, we present the safety and efficacy of venetoclax + azacitidine in patients with R/R MDS. This phase 1b, open-label, multicenter study enrolled patients >/=18 years. Patients were treated with escalating doses of oral venetoclax: 100, 200, or 400 mg daily for 14 days every 28-day cycle. Azacitidine was administered on Days 1-7 every cycle at 75 mg/m(2) /day intravenously/subcutaneously. Responses were assessed per modified 2006 International Working Group (IWG) criteria. Forty-four patients (male 86%, median age 74 years) received venetoclax + azacitidine treatment. Median follow-up was 21.2 months. Hematological adverse events of Grade >/= 3 included febrile neutropenia (34%), thrombocytopenia (32%), neutropenia (27%), and anemia (18%). Pneumonia (23%) was the most common Grade >/= 3 infection. Marrow responses were seen including complete remission (CR, n = 3, 7%) and marrow CR (mCR, n = 14, 32%); 36% (16/44) achieved transfusion independence (TI) for RBCs and/or platelets, and 43% (6/14) with mCR achieved hematological improvement (HI). The median time to CR/mCR was 1.2 months, and the median duration of response for CR + mCR was 8.6 months. Median OS was 12.6 months. Venetoclax + azacitidine shows activity in patients with R/R MDS following prior HMA therapy failure and provides clinically meaningful benefits, including HI and TI, and encouraging OS.
Publisher
Wiley
Keywords
Aged; Humans; Male; *Antineoplastic Combined Chemotherapy Protocols/adverse effects; Azacitidine/therapeutic use; Leukemia, Myeloid, Acute/drug therapy; *Myelodysplastic Syndromes/drug therapy; Neutropenia/chemically induced; Sulfonamides; Treatment Outcome; Female
Department(s)
Clinical Haematology
PubMed ID
36309981
Open Access at Publisher's Site
https://doi.org/10.1002/ajh.26771
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-06-15 07:25:01
Last Modified: 2023-06-15 07:25:48

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙